Navigation Links
Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Date:11/19/2007

Commences Phase I Clinical Trial of Proprietary siRNA Molecule in Acute

Renal Failure

FREMONT, Calif., Nov. 19 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it has commenced systemic dosing in humans of its proprietary product candidate, AKIi-5, a siRNA compound discovered and developed by Quark for the treatment of Acute Renal Failure (ARF), also called Acute Kidney Injury (AKI). Based on publicly available information, Quark believes that this is the first human clinical trial involving the systemic delivery of siRNA.

The Phase I clinical trial is a multi-center, double-blind, placebo controlled, dose-escalation trial assessing the safety and pharmacokinetics of AKIi-5 administered intravenously as a single dose to patients undergoing major cardiac surgery. Patients will be enrolled in the trial in a number of centers in the United States, Europe and Israel. Quark expects to complete the trial in early 2008. Depending on the results of this trial, Quark expects to initiate a dose-ranging Phase II clinical trial measuring AKIi-5 clinical activity.

Daniel Zurr, Chief Executive Officer, commented, "The initiation of human dosing in our Phase I trial in ARF signifies a very important step in Quark's clinical program and marks an important milestone in the RNAi industry. For Quark, the trial serves to further validate the strength of our pipeline and our overall expertise in the RNAi arena. With AKIi-5 now in the clinic, RTP801i-14, which we licensed to Pfizer, in a Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration, AHLi-11 in IND-enabling studies and additional RNAi-based candidate drugs in pre-clinical testing, we believe Quark has one of the most robust RNAi product portfolios in the industry.

"For the RNAi industry, the trial m
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Northstar Global Business Services, ... months of hard work from many talented specialists, ... formulation and package design.  The new formulation for ... into the product due to overwhelming evidence of ... Snorenz Nighttime will also include these vitamins, as ...
(Date:8/20/2014)... , Aug. 20, 2014  The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kentucky blocked the sale of ...
(Date:8/20/2014)...  The National Association of Drug Diversion Investigators ... the real-time, pseudoephedrine (PSE) blocking system in Missouri. The ... (NPLEx), automatically blocks unlawful pseudoephedrine sales and helps ... make arrests. Data released by NPLEx shows electronic ... the sale of more than 19,030 boxes of medicine ...
Breaking Medicine Technology:Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
(Date:8/21/2014)... 21, 2014 Pulmonary Hypertension Association ... Education Forum for PH patients and families to ... Pulmonary Hypertension Association – the country’s leading ... to prevent and cure pulmonary hypertension (PH) – ... functioning of the heart and can lead right ...
(Date:8/21/2014)... have pinpointed the environmental source of fungal infections that ... decades. It literally grows on trees. , The discovery ... girl, who spent the summer gathering soil and tree ... infections of the fungus named Cryptococcus gattii ... encompasses a number of species including C. gattii ...
(Date:8/21/2014)... mothers are less likely than white moms to breast-feed ... in neighborhoods with many black residents do less to ... residents, a U.S. government study finds. Key practices ... centers where the black population is higher than average, ... Prevention reported Thursday. These practices include efforts to ...
(Date:8/21/2014)... 21, 2014 (HealthDay News) -- Among seniors, dimming vision ... The study involved more than 2,500 people, aged 65 to ... and again two, six and eight years later. Vision ... person,s risk of death during the study period, the researchers ... researchers led by Sharon Christ of Purdue University in West ...
(Date:8/21/2014)... 2014 Transvaginal mesh lawsuits ... to move forward in the federal multidistrict litigation ... West Virginia, Bernstein Liebhard LLP reports. According to ... Court has established new stipulated evidence preservation protocols ... storage and preservation. (In re C.R. Bard Inc. ...
Breaking Medicine News(10 mins):Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 3Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3
... the standard treatment regimen for hepatitis C significantly increases the ... to a research report published Monday in the online edition ... team, led by Paul Kwo, M.D., of Indiana University School ... treatment,s effectiveness when given for 48 weeks in one treatment ...
... by researchers at the Bradley Hasbro Children,s Research Center ... some of the well-documented ethnic disparities in pediatric asthma. ... children in the study tended to think they were ... tests actually revealed normal lung function. According to ...
... Adding a direct acting anti-viral drug to the standard ... in the most difficult to treat patients, according to a ... journal The Lancet . The research team, led ... reported that adding the drug nearly doubled the treatment,s effectiveness ...
... The University of Colorado College of Nursing has been ... Health and Human Services, Health Resources and Services Administration ... to provide leadership for high quality healthcare in rural ... a competitively awarded grant to i-LEAD, Innovation in Leadership ...
... Reporter , FRIDAY, Aug. 6 (HealthDay News) -- "Locally grown" ... It,s a concept that has made many Americans scan their ... been raised nearby. But are locally grown foods necessarily ... grown locally will be much healthier; others, not so much. ...
... 2010 SIRIUS XM Radio (NASDAQ: SIRI) today announced ... Doctor Radio Reports: Understanding Autism - Looking for Answers, ... Perri Peltz on which a panel of world-class doctors, ... the latest research and treatment options for autism and ...
Cached Medicine News:Health News:New antiviral drug shows promise for dramatic improvement in hepatitis C treatment 2Health News:New antiviral drug shows promise for dramatic improvement in hepatitis C treatment 3Health News:Latino children with asthma less accurate in determining their lung function 2Health News:New anti-viral drug shows promise for dramatic improvement in hepatitis C treatment 2Health News:New anti-viral drug shows promise for dramatic improvement in hepatitis C treatment 3Health News:College of Nursing awarded grant for nursing leadership in rural and underserved areas 2Health News:College of Nursing awarded grant for nursing leadership in rural and underserved areas 3Health News:'Locally Grown' May Mean Healthier, But Not Always 2Health News:'Locally Grown' May Mean Healthier, But Not Always 3Health News:Sirius XM to broadcast 'Doctor Radio Reports: Understanding Autism -- Looking for Answers' 2
... frames are designed with the safety and comfort ... Schott RS-520 (also called SF-6) leaded glass, the ... meet standards, as set for optical clarity, visible ... our eyewear is protecting your eyes, it also ...
... with the safety and comfort of the practitioner ... called SF-6) leaded glass, the industry standard for ... set for optical clarity, visible light transmission, power ... protecting your eyes, it also helps you look ...
... lenses and frames are designed with the safety ... lenses are Schott RS-520 (also called SF-6) leaded ... These lenses meet standards, as set for optical ... ,While our eyewear is protecting your eyes, ...
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
Medicine Products: